A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors
2005 ◽
Vol 23
(16_suppl)
◽
pp. 3007-3007
◽
2011 ◽
Vol 29
(15_suppl)
◽
pp. 3020-3020
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 3008-3008
◽